share_log

Prime Medicine Analyst Ratings

Prime Medicine Analyst Ratings

Prime 医学分析师评级
Benzinga ·  2023/11/07 15:20
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/07/2023 211.19% JP Morgan $27 → $26 Maintains Overweight
10/09/2023 127.41% BMO Capital → $19 Initiates Coverage On → Outperform
09/06/2023 139.38% JonesTrading → $20 Initiates Coverage On → Buy
08/14/2023 127.41% Morgan Stanley $21 → $19 Maintains Equal-Weight
07/31/2023 187.25% Guggenheim → $24 Initiates Coverage On → Buy
04/18/2023 115.44% Stifel → $18 Initiates Coverage On → Buy
01/24/2023 151.35% Morgan Stanley $23 → $21 Maintains Equal-Weight
11/14/2022 223.16% JP Morgan → $27 Initiates Coverage On → Overweight
11/14/2022 199.22% Jefferies → $25 Initiates Coverage On → Buy
11/14/2022 175.28% Morgan Stanley → $23 Initiates Coverage On → Equal-Weight
11/14/2022 163.32% Goldman Sachs → $22 Initiates Coverage On → Neutral
日期 上行/下行 分析公司 目标价格变动 评级变动 之前/当前的评级
11/07/2023 211.19% 摩根大通 27 美元 → 26 美元 维护 超重
2023 年 9 月 10 日 127.41% BMO Capital → 19 美元 启动覆盖范围开启 → 跑赢大盘
09/06/2023 139.38% JonesTrading → 20 美元 启动覆盖范围开启 → 购买
08/14/2023 127.41% 摩根士丹利 21 美元 → 19 美元 维护 重量相等
07/31/2023 187.25% 古根海姆 → 24 美元 启动覆盖范围开启 → 购买
04/18/2023 115.44% Stifel → 18 美元 启动覆盖范围开启 → 购买
01/24/2023 151.35% 摩根士丹利 23 美元 → 21 美元 维护 重量相等
11/14/2022 223.16% 摩根大通 → 27 美元 启动覆盖范围开启 → 超重
11/14/2022 199.22% 杰富瑞集团 → 25 美元 启动覆盖范围开启 → 购买
11/14/2022 175.28% 摩根士丹利 → 23 美元 启动覆盖范围开启 → 重量相等
11/14/2022 163.32% 高盛 → 22 美元 启动覆盖范围开启 → 中立

What is the target price for Prime Medicine (PRME)?

Prime Medicine（PRME）的目标价格是多少？

The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JP Morgan on November 7, 2023. The analyst firm set a price target for $26.00 expecting PRME to rise to within 12 months (a possible 211.19% upside). 11 analyst firms have reported ratings in the last year.

摩根大通于2023年11月7日公布了Prime Medicine（纳斯达克股票代码：PRME）的最新目标股价。该分析公司将目标股价定为26.00美元，预计PRME将在12个月内升至12个月内（可能上涨211.19％）。去年有11家分析公司公布了评级。

What is the most recent analyst rating for Prime Medicine (PRME)?

分析师对Prime Medicine（PRME）的最新评级是多少？

The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JP Morgan, and Prime Medicine maintained their overweight rating.

摩根大通对Prime Medicine（纳斯达克股票代码：PRME）的最新分析师评级由摩根大通提供，Prime Medicine维持增持评级。

When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?

Prime Medicine（PRME）的下一个分析师评级何时公布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.

分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表、与Prime Medicine的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Prime Medicine的最新评级是在2023年11月7日发布的，因此您应该预计下一个评级将在2024年11月7日左右公布。

Is the Analyst Rating Prime Medicine (PRME) correct?

分析师对 Prime Medicine (PRME) 的评级正确吗？

While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a maintained with a price target of $27.00 to $26.00. The current price Prime Medicine (PRME) is trading at is $8.36, which is out of the analyst's predicted range.

尽管评级是主观的，并且会发生变化，但最新的Prime Medicine（PRME）评级保持不变，目标股价为27.00美元至26.00美元。Prime Medicine（PRME）目前的交易价格为8.36美元，超出了分析师的预期区间。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发